The Fund supports networks of state health policy decision makers to help identify, inspire, and inform policy leaders.
The Milbank Memorial Fund supports two state leadership programs for legislative and executive branch state government officials committed to improving population health.
The Fund identifies and shares policy ideas and analysis to advance state health leadership, strong primary care, and sustainable health care costs.
Keep up with news and updates from the Milbank Memorial Fund. And read the latest blogs from our thought leaders, including Fund President Christopher F. Koller.
The Fund publishes The Milbank Quarterly, as well as reports, issues briefs, and case studies on topics important to health policy leaders.
The Milbank Memorial Fund is is a foundation that works to improve population health and health equity.
Quarterly Department
Quarterly Article
November 2025 ANDRE NOGUEIRA, MARGARET M. FITZPATRICK, ASHLEY GRESH, KENNEDY MCDANIEL, TIFFANY J. RISER, TERRANCE LINDSAY, RANDI WOODS, ADEDOYIN EISAPE, LISA STAMBOLIS, ALICIA COOKE, BRUCE LEFF, ELIANA PERRIN, REGINA HAMMOND, Sarah L. Szanton,
Despite spending more per capita on healthcare than any other nation, the United States experiences declining life expectancy and increasing chronic disease burden—a paradox reflecting fundamental limitations in the current treatment-centered, facility-based care system. This paper introduces Neighborhood Nursing, an innovative universal care infrastructure designed to shift the US healthcare toward proactive, prevention-centered care organized geographically in neighborhoods. More
September 2025 Pankaj Jain, Bhav Jain, Rushabh Doshi, Urvish Jain, Henry Claypool, Ariana Aboulafia, Bonnielin K. Swenor,
Throughout the last 50 years, the disability rights movement has made significant progress in providing statutory protections for people with disabilities in the United States. More
August 2025 LORI DORFMAN, Sarah E. Gollust, MAKANI THEMBA, PRITPAL S. TAMBER, Anthony Iton,
A growing body of scholarship and practice in public health attests to the importance of addressing differences in power as a fundamental determinant of health inequities. To pursue health equity, public health practitioners must move beyond identifying differences in health outcomes among populations (disparities) to articulating why those differences are unfair or unjust (inequities) and then identifying structures, such as laws, policies, practices, and norms, that advantage some and disadvantage others. More
August 2025 Philip M. Alberti,
For more than 2 years, I have started my speaking engagements with a simple message: “Health equity benefits all communities.” Although the message may be straightforward, health equity–focused scientists and advocates like me have done an inadequate and ineffective job making that point clear and believable through stories, data, and messaging. More
August 2025 Rick Mayes, Micah Johnson,
From 2004 to 2024, Medicare Advantage (MA) went from being a “policy disappointment,” covering 12% of all Medicare beneficiaries, to predominance, covering more than one-half (52%), with more growth predicted in the future. Drawing on an extensive review and synthesis of the literature, Medicare Payment Advisory Commission (MedPAC) reports, congressional committee hearings, and Centers for Medicare and Medicaid Services (CMS) data, this paper analyzes the evolution of Medicare and managed care in three parts More
July 2025 Gabriela Plasencia, Kamaria Kaalund, Olurotimi Kukoyi, Viviana Martinez-Bianchi, Andrea Thoumi,
Populations that identify as Latino/a/e/x or Hispanic (herein referred to as Latine) in the United States continue to face disproportion-ate health and socioeconomic challenges that were exacerbated during the COVID-19 pandemic and persist in the current political climate. More
June 2025 Hannah Rahim, Aaron S. Kesselheim,
Prescription drug prices in the United States are substantially higher than in other high-income countries, with US prices reported to be an average of 2.78 times those of other countries in the Organisation for Economic Co-operation and Development.1 In response to these high prices, along with an opaque supply chain that can lead to substantial discrepancies in prices across different payors, states have passed drug price transparency laws that require manufacturers to disclose information on drug prices. More
June 2025 MATTHEW S. McCOY, MARTHA E. GAINES, STEVEN JOFFE, Genevieve Pham-Kanter, EMILY A. LARGENT, Bernard Lo, HOLLY FERNANDEZ LYNCH, ALLISON M. WHELAN, Michelle M. Mello,
Leaders at many of the country’s top academic medical centers earned—in addition to their institutional salaries—hundreds of thousands of dollars a year as directors of pharmaceutical and device companies. Critics have urged academic institutions to rethink conflict of interest policies governing leaders’ outside activities, which are understood to pose not only individual conflicts for leaders themselves but also institutional conflicts for their academic employers. More
June 2025 Dennis P. Scanlon, Jillian B. Harvey, Cheryl L. Damberg, Pratiksha Mahendra Bhagat, Yunfeng Shi,
In this article, we discuss why reliance on transaction prices and market share alone is not sufficient for effective health policy development and regulatory enforcement in health care markets that are imperfectly competitive. We discuss the need to better measure the output produced by health care suppliers and to capture the costs of producing that output. More
June 2025 Raquel Burgess, Tanja Srebotnjak, Christine Lin, Lawrence Grierson, Daniel C. Esty, Yusuf Ransome, Nicholas Freudenberg,
This article seeks to advance discussion on two key priorities related to the commercial determinants of health (CDH): 1) the development of mechanisms to measure and monitor the practices of commercial entities, and 2) the development of effective policy recommendations for addressing the CDH. More